MA27624A1 - Procede pour realiser une preparation enrobee - Google Patents
Procede pour realiser une preparation enrobeeInfo
- Publication number
- MA27624A1 MA27624A1 MA28453A MA28453A MA27624A1 MA 27624 A1 MA27624 A1 MA 27624A1 MA 28453 A MA28453 A MA 28453A MA 28453 A MA28453 A MA 28453A MA 27624 A1 MA27624 A1 MA 27624A1
- Authority
- MA
- Morocco
- Prior art keywords
- making
- coated preparation
- preparation
- pioglitazone hydrochloride
- coated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention divulgue une méthode de réalisation d'une préparation enrobée de chlorhydrate de pioglitazone, qui est utile comme agent thérapeutique pour le diabète et semblables, et qui est meilleure par les caractéristiques de la préparation telles la propriété de dissolution du chlorhydrate de pioglitazone.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003020925 | 2003-01-29 | ||
JP2003276894 | 2003-07-18 | ||
JP2004001128 | 2004-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27624A1 true MA27624A1 (fr) | 2005-11-01 |
Family
ID=32830627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28453A MA27624A1 (fr) | 2003-01-29 | 2005-08-24 | Procede pour realiser une preparation enrobee |
Country Status (14)
Country | Link |
---|---|
US (1) | US7976853B2 (fr) |
EP (1) | EP1588708A4 (fr) |
KR (1) | KR101114808B1 (fr) |
AU (1) | AU2004208606B2 (fr) |
BR (1) | BRPI0407074A (fr) |
CA (1) | CA2514539C (fr) |
CR (1) | CR7929A (fr) |
IL (1) | IL169870A (fr) |
MA (1) | MA27624A1 (fr) |
MX (1) | MXPA05007883A (fr) |
NO (1) | NO20053965L (fr) |
NZ (1) | NZ541749A (fr) |
PL (1) | PL377403A1 (fr) |
WO (1) | WO2004067001A1 (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
CN1874774B (zh) | 2003-10-31 | 2011-04-13 | 武田药品工业株式会社 | 包含胰岛素致敏剂、胰岛素促分泌素和聚氧乙烯脱水山梨醇脂肪酸酯的固体制剂 |
EP1738754B1 (fr) | 2004-04-14 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Preparation pharmaceutique solide |
GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
TWI274889B (en) * | 2005-10-06 | 2007-03-01 | Elan Microelectronics Corp | Resistive touch screen measurement system |
MY149306A (en) | 2005-12-22 | 2013-08-30 | Takeda Pharmaceutical | Solid preparation containing an insulin sensitizer |
WO2008018569A1 (fr) * | 2006-08-10 | 2008-02-14 | Takeda Pharmaceutical Company Limited | Composition pharmaceutique |
TW201350143A (zh) * | 2007-02-01 | 2013-12-16 | Takeda Pharmaceutical | 固體型製劑 |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
WO2009018453A1 (fr) | 2007-07-31 | 2009-02-05 | Lifescan, Inc. | Différenciation de cellules souches embryonnaires humaines |
CN101878298B (zh) | 2007-11-27 | 2017-08-15 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
BRPI0908033A2 (pt) | 2008-02-21 | 2015-08-04 | Centocor Ortho Biotech Inc | Método placas de superfície modificada e composições para adesão, cultura e desprendimento de célula |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
WO2009120844A2 (fr) * | 2008-03-26 | 2009-10-01 | Teva Pharmaceutical Industries Ltd. | Compositions pharmaceutiques comprenant un sensibilisateur à l’insuline et un secrétagogue d’insuline |
PL2942392T3 (pl) | 2008-06-30 | 2019-02-28 | Janssen Biotech, Inc | Różnicowanie pluripotencjalnych komórek macierzystych |
EP2346988B1 (fr) | 2008-10-31 | 2017-05-31 | Janssen Biotech, Inc. | Différenciation de cellules souches embryonnaires humaines en la lignée endocrine pancréatique |
MX2011005289A (es) | 2008-11-20 | 2011-06-01 | Centocor Ortho Biotech Inc | Metodos y composiciones para union y cultivo celular sobre sustratos planares. |
KR101774546B1 (ko) | 2008-11-20 | 2017-09-04 | 얀센 바이오테크 인코포레이티드 | 마이크로-캐리어 상의 만능 줄기 세포 배양 |
EP2456862A4 (fr) | 2009-07-20 | 2013-02-27 | Janssen Biotech Inc | Différentiation de cellules souches embryonnaires humaines |
RU2701335C2 (ru) | 2009-12-23 | 2019-09-25 | Янссен Байотек, Инк. | Способ получения популяции панкреатических эндокринных клеток, соэкспрессирующих nkx6.1 и инсулин, и способ лечения диабета |
SG183535A1 (en) | 2010-03-01 | 2012-10-30 | Janssen Biotech Inc | Methods for purifying cells derived from pluripotent stem cells |
EP2569419B1 (fr) | 2010-05-12 | 2019-03-20 | Janssen Biotech, Inc. | Différentiation de cellules souches embryonnaires humaines |
EP2611910B1 (fr) | 2010-08-31 | 2018-01-17 | Janssen Biotech, Inc. | Différenciation de cellules souches embryonnaires humaines |
EP3372672A1 (fr) | 2010-08-31 | 2018-09-12 | Janssen Biotech, Inc. | Différenciation de cellules souches embryonnaires humaines |
EP2611434A1 (fr) | 2010-09-01 | 2013-07-10 | Lupin Limited | Composition pharmaceutique contenant de la metformine et de la pioglitazone |
US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
MX2014007744A (es) | 2011-12-22 | 2015-01-12 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal. |
SG11201405052RA (en) | 2012-03-07 | 2014-10-30 | Janssen Biotech Inc | Defined media for expansion and maintenance of pluripotent stem cells |
CA2875786C (fr) | 2012-06-08 | 2022-12-06 | Janssen Biotech, Inc. | Differenciation des cellules souches embryonnaires d'origine humaine en cellules endocrines pancreatiques |
EP2674149B1 (fr) * | 2012-06-15 | 2017-10-04 | Shin-Etsu Chemical Co., Ltd. | Procédé de préparation de granules composites comprenant de la cellulose hydroxypropyle faiblement substituée et préparation à libération rapide |
CN105008518B (zh) | 2012-12-31 | 2020-08-07 | 詹森生物科技公司 | 在空气-液体界面处培养人胚胎干细胞以用于分化成胰腺内分泌细胞 |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
EP2938722B1 (fr) | 2012-12-31 | 2021-12-08 | Janssen Biotech, Inc. | Mise en suspension et agrégation de cellules pluripotentes humaines pour la différenciation en cellules endocrines du pancréas |
US10138465B2 (en) | 2012-12-31 | 2018-11-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells into pancreatic endocrine cells using HB9 regulators |
MX362930B (es) * | 2013-06-17 | 2019-02-26 | Nippon Soda Co | Agente de recubrimiento que comprende celulosa de hidroxialquilo. |
KR101597004B1 (ko) * | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
KR102162138B1 (ko) | 2014-05-16 | 2020-10-06 | 얀센 바이오테크 인코포레이티드 | 췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도 |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
RU2690677C1 (ru) * | 2018-06-27 | 2019-06-05 | Георгий Георгиевич Чумбуридзе | Стабилизированная композиция, обладающая противовирусной, противоопухолевой, иммуномодулирующей, актопротекторной, антимутагенной и антиоксидантной активностью |
CN112461947B (zh) * | 2020-10-27 | 2022-06-28 | 山东省药学科学院 | 一种盐酸吡格列酮片溶出曲线的测定方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5179716A (en) | 1974-12-28 | 1976-07-12 | Shinetsu Chemical Co | Kokeiiyakuseizaino seizohoho |
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
DE69322764T2 (de) * | 1992-10-09 | 1999-05-06 | Kanegafuchi Chemical Ind | Herstellungsmethode für feines granulat |
US5651983A (en) | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
ATE376829T1 (de) * | 1993-09-15 | 2007-11-15 | Daiichi Sankyo Co Ltd | Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm) |
TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
US6291495B1 (en) | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
SE9702000D0 (sv) | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
US20020004515A1 (en) | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
KR20060105005A (ko) | 1997-06-18 | 2006-10-09 | 스미스클라인비이참피이엘시이 | 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료 |
AP1224A (en) | 1998-03-19 | 2003-11-14 | Bristol Myers Squibb Co | Biphasic controlled release delivery system for high solubility pharmaceuticals and method. |
WO2000016776A1 (fr) | 1998-09-18 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Preparations a administrer par voie buccale a liberation lente |
KR20010082251A (ko) | 1998-10-26 | 2001-08-29 | 찌바따 이찌로, 다나까 도시오 | 서방성 입자 |
DE69939485D1 (de) | 1998-11-12 | 2008-10-16 | Smithkline Beecham Plc | Arzneimittel zur gesteuerten freisetzung eines insulin sensibilisators und metformin |
AR023700A1 (es) | 1998-11-12 | 2002-09-04 | Smithkline Beecham Plc | Un procedimiento para preparar una composicion farmaceutica que comprende un sensibilizador de insulina |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6168806B1 (en) * | 1999-03-05 | 2001-01-02 | Fang-Yu Lee | Orally administrable nifedipine pellet and process for the preparation thereof |
WO2001035940A2 (fr) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Nouvelle composition et utilisation |
MY125516A (en) | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
CA2399463A1 (fr) * | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Combinaison de medicament |
US6403121B1 (en) * | 2000-05-01 | 2002-06-11 | Aeropharm Technology Incorporated | Core formulation |
US6524621B2 (en) | 2000-05-01 | 2003-02-25 | Aeropharm Technology Inc. | Core formulation |
US6780432B1 (en) | 2000-05-01 | 2004-08-24 | Aeropharm Technology, Inc. | Core formulation |
US6610272B1 (en) * | 2000-05-01 | 2003-08-26 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
JP2001342185A (ja) * | 2000-06-02 | 2001-12-11 | Nichiko Pharmaceutical Co Ltd | フィルムコーティングされた塩酸ラニチジン錠剤 |
MXPA03006217A (es) | 2001-01-12 | 2004-10-15 | Sun Pharmaceutical Ind Ltd | Sistema de administracion espaciada de farmacos. |
WO2002060448A1 (fr) * | 2001-01-30 | 2002-08-08 | Teijin Limited | Composition medicinale |
MXPA04000180A (es) | 2001-07-10 | 2004-11-22 | Kos Life Sciences Inc | Formulacion de nucleo que comprende hidrocloruro de pioglitazona y una biguanida. |
US20030187074A1 (en) | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
WO2003105809A1 (fr) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes |
EP1552832A1 (fr) | 2002-07-11 | 2005-07-13 | Takeda Pharmaceutical Company Limited | Procede de production d'une preparation recouverte |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
CA2499597C (fr) | 2002-09-20 | 2012-01-17 | Unchalee Kositprapa | Nouvelle preparation pharmaceutique contenant un biguanide et un derive de la thiazolidinedione |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
IN192749B (fr) * | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
WO2004069229A1 (fr) | 2003-02-05 | 2004-08-19 | Ipca Laboratories Limited | Medicaments antidiabetiques a double liberation et procede de production de ceux-ci |
-
2004
- 2004-01-28 MX MXPA05007883A patent/MXPA05007883A/es active IP Right Grant
- 2004-01-28 US US10/542,997 patent/US7976853B2/en active Active
- 2004-01-28 KR KR1020057013940A patent/KR101114808B1/ko not_active IP Right Cessation
- 2004-01-28 AU AU2004208606A patent/AU2004208606B2/en not_active Ceased
- 2004-01-28 PL PL377403A patent/PL377403A1/pl not_active Application Discontinuation
- 2004-01-28 CA CA2514539A patent/CA2514539C/fr not_active Expired - Fee Related
- 2004-01-28 WO PCT/JP2004/000754 patent/WO2004067001A1/fr not_active Application Discontinuation
- 2004-01-28 BR BR0407074-7A patent/BRPI0407074A/pt not_active Application Discontinuation
- 2004-01-28 NZ NZ541749A patent/NZ541749A/en not_active IP Right Cessation
- 2004-01-28 EP EP04705948A patent/EP1588708A4/fr not_active Withdrawn
-
2005
- 2005-07-25 IL IL169870A patent/IL169870A/en not_active IP Right Cessation
- 2005-08-01 CR CR7929A patent/CR7929A/es unknown
- 2005-08-24 MA MA28453A patent/MA27624A1/fr unknown
- 2005-08-25 NO NO20053965A patent/NO20053965L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CR7929A (es) | 2005-11-28 |
EP1588708A1 (fr) | 2005-10-26 |
KR20050096958A (ko) | 2005-10-06 |
MXPA05007883A (es) | 2005-09-21 |
AU2004208606B2 (en) | 2009-09-24 |
IL169870A (en) | 2012-07-31 |
US20060141128A1 (en) | 2006-06-29 |
PL377403A1 (pl) | 2006-02-06 |
KR101114808B1 (ko) | 2012-02-15 |
CA2514539A1 (fr) | 2004-08-12 |
CA2514539C (fr) | 2012-03-06 |
NO20053965L (no) | 2005-08-25 |
AU2004208606A1 (en) | 2004-08-12 |
US7976853B2 (en) | 2011-07-12 |
EP1588708A4 (fr) | 2006-03-01 |
WO2004067001A1 (fr) | 2004-08-12 |
BRPI0407074A (pt) | 2006-01-24 |
NZ541749A (en) | 2009-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27624A1 (fr) | Procede pour realiser une preparation enrobee | |
TWI262805B (en) | Pharmaceutical composition for treating or inhibiting colonic polyps | |
HK1070651A1 (en) | Process for the manufacture of hmg-coa reductase inhibitors | |
BR0214164A (pt) | Ligantes do receptor canabinóide | |
TNSN06369A1 (fr) | Derives de tetrahydronaphtyridine utiles comme ligands du recepteur d'histamine h3 | |
SE0202483D0 (sv) | Chemical compounds | |
EA200602196A1 (ru) | Производные пиразола, композиции, содержащие эти соединения, и способы применения | |
CA2506016A1 (fr) | Derives de 3-amino-piperadine et leurs procedes de preparation | |
HK1085675A1 (en) | Anticancer compounds | |
NO20014101L (no) | Stabilisert oral farmasöytisk blanding inneholdende iodid og iodat og fremgangsmåte | |
EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
PL371127A1 (en) | 6-aminomorphinane derivatives, method for the production and use thereof | |
AU2003250471A1 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
AP1766A (en) | Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation. | |
SE0200919D0 (sv) | Chemical compounds | |
MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
MY138826A (en) | 2,7-substituted indoles | |
DE60206762D1 (de) | Hexahydroazepino[4,5-g]indole und -indoline als 5-ht-rezeptor-liganden | |
EA200000322A1 (ru) | Способ синтеза производных хинолина | |
DE60225694D1 (de) | Fexofenadine hydrochlorid polymorph | |
WO2003080631A8 (fr) | Inhibiteurs de plasma carboxypeptidase b | |
EP1734037A3 (fr) | Procédé pour la préparation du (R)-G(A)-(2,3-dimethoxyphenyle)-1-[2-(4-fluorophenyle)ethyle]-4-piperidinemethanol | |
WO2003076426A3 (fr) | Composes therapeutiques | |
EA200300850A1 (ru) | Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах | |
SE9704770D0 (sv) | New use |